A study looking at the feasibility of using repeated sampling of validated digital measures at home, in patients with early-stage Alzheimer’s Disease (AD), has completed enrollment for a multi-site study.
Redx has been presented with a commemorative plaque at its HQ at Alderley Park, in recognition of its discovery of pirtobrutinib, the active pharmaceutical ingredient (API) in Eli Lilly's cancer treatment Jaypirca.
A previously announced research collaboration between Gilead Sciences and Arcus Biosciences that was focused on oncology has been expanded to include inflammatory diseases therapies.
Xequel Bio has selected Societal CDMO to support the ongoing clinical development of a patented new chemical entity based on its aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform.
Vedanta Biosciences has obtained fast track designation from the US Food and Drug Administration (FDA) for its live biotherapeutic VE303, a preventative treatment for recurrent Clostridioides difficile infection (CDI).
Results from a multinational trial of trifluridine/tipracil, known as Lonsurf, with or without bevacizumab in refractory metastatic colorectal cancer (mCRC) have resulted in statistically significantly and clinically meaningful improvements.
A single-agent treatment for patients with relapsed or refractory myelodysplastic neoplasms has shown promising results, including overall survival, in a study.
Scorpion Therapeutics, a clinical-stage oncology company, has announced that the first patient has been dosed in a phase 1/2 clinical trial of STX-478, its treatment for breast cancer and other solid tumors.
Galapagos NV has announced it has initiated a phase 3 study with small molecule drug filgotinib in patients with the chronic, highly inflammatory condition, active axial spondyloarthritis(AxSpA).
The company announces plans to reorganize its business to focus on design-and-deployment engagements for on-site implementation of automated cloud labs.
A drug to treat a rare cancer that grows where the esophagus and stomach join has been accepted for review by the China National Medical Products Administration (NMPA).
Aerona Clinical is a medium sized pharmaceutical company, represented not only in the United Kingdom, but in Europe, and with a global reach. The company has been operating in this environment in the pharma industry for 15 to 20 years.
The German and Spanish companies use their relevant expertise in conjunction to provide clients with services spanning from hit generation to pre-clinical development.
The Institute for Population and Precision Health (IPPH) at the University of Chicago has joined private biotech company, Freenome, to become its partner as part of a study.
Unifying medicinal development processes and data within a connected technology ecosystem will enhance collaboration, two partnering companies using a development cloud have said.
A partnership was announced this week (April 11) between non-profit CureDuchenne and health technology company, PicnicHealth that will provide as much data as possible to researchers while helping patients navigate complex medical systems.
Dutch biopharmaceutical company, Pharming Group PV, has sent its first commercial shipments of a drug to treat a rare, primary immunodeficiency, to the US.
TWO US clinical investigator sites have been opened for a phase 1 clinical trial for patients with soft tissue sarcoma and the first patient has been dosed.
The naloxone hydrochloride nasal spray will be made available over-the-counter, therefore not requiring a prescription, in an effort to reduce deaths from opioid abuse.
Finding a treatment for a skin disease that significantly diminishes the quality of life for those living with it has moved forward to the next phase of trials.
In its bid to what it says will make participation in clinical trials easier and more sustainable, Greenphire has revealed a patient-powered registry and it has also expanded a deal with Merck.
A powerful tool that could capture abdominal aortic aneurysms (AAA) and refer those at risk is the first to be given clearance by the US Food and Drink Administration (FDA).
The company launches its new ZS300 sensor, ZB200 bridge and Android sensor discovery app, which will be made available for use with the supply chains of the pharma and food industries.
Challenging target profiles can be targeted more efficiently than traditional drug discovery using Exscientia’s AI-driven precision design platform, its CEO says.
In the second and final part of an interview with Medable’s chief growth officer and women’s health champion, Sanskriti Thakur, discover her views on vital changes that need to be made. She discusses ways to ensure the importance of women’s roles in clinical...
Non-clinical research has been published about roginolisob, iOnctura’s non-ATP competitive alloseteric modulator of PI3Kδ, for the potential treatment of patients with solid and hematological tumors.
The funding will be split between 17 US non-profit organizations this year, as the company reveals the broader progress it has made towards its long-term inclusion and diversity goals.
Despite diversity being spoken about more than ever before, research discovers clinical trials are less representative of the US population compared to a decade prior.
Positive data from a phase 2 clinical trial has proven the general mechanism of action of SK channel inhibition for treatment of atrial fibrillation (AF), an abnormal heart rhythm.
After completing the acquisition of Aveo, the Korean chemical company wants its subsidiary to become a global leader in the therapeutic area within five years.
Poolbeg Pharma plc has been granted a patent by the US Patent and Trademark Office (USPTO) for ways of treating hypercytokinaemia using a small molecule immunomodulator.
Charité – Universitätsmedizin Berlin, one of Europe’s largest university hospitals is collaborating with UK-based Exscientia to make use of an artificial intelligence-driven precision medicine platform in haematological cancers.
When the pandemic broke, the whole world was thrown onto a steep learning curve. Everyone had to find new ways to adapt in their day to day lives as well as their working lives. There was no exception with clinical trials, with patients unable to attend...
Patient recruitment and retention is an ongoing issue for everyone working in the clinical trials field. Over recent weeks, OSP has interviewed or spoken to a number of companies about their solutions.
The two partners will pool capabilities to provide an expanded service to their clients, which will see Koneksa provide its digital biomarkers tools and SSI Strategy its expertise in drug development.
UC San Francisco will conduct a six-month clinical trial on hypertrophic cardiomyopathy, which will rely on feedback from Vivalink’s biometric data platform.
Our world is getting greener – or at least trying to with more people turning to electric vehicles, buying local seasonal fruit and vegetables, cafes and restaurants adopting paper straws and a growth in sales of eco-friendly home products, to name a...
